Kyverna Therapeutics, Inc Common Stock

Yahoo Finance • 6 days ago

Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary... Full story

Yahoo Finance • 10 days ago

The Oncology Institute Names Minh Merchant Chief Legal Officer

TOI Management, LLC CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joine... Full story

Yahoo Finance • last month

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) EMERYVILLE, Calif., March... Full story

Yahoo Finance • 4 months ago

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story

Yahoo Finance • 4 months ago

Biggest stock movers Tuesday: RILY, ORGO, KYTX, RC, LWLG and more

[Stock Market] sweetym/iStock via Getty Images U.S. stock futures retreated Tuesday as investors adopted a cautious stance ahead of November’s employment data, a key indicator for the labor market’s health. Here are some of Tuesday's big... Full story

Yahoo Finance • 5 months ago

Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04

* Kyverna Therapeutics press release [https://seekingalpha.com/pr/20305094-kyverna-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial] (KYTX [https://seekingalpha.com/symbol/KYTX]): Q3 GAAP EPS of -$0.85 misse... Full story

Yahoo Finance • 5 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive interim Phase 2 data in generalized myast... Full story

Yahoo Finance • 6 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful responses in MG-ADL and QMG... Full story

Yahoo Finance • 6 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consiste... Full story

Yahoo Finance • 6 months ago

Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout

Kyverna Therapeutics Inc. (NASDAQ:KYTX) is one of the best young stocks with huge upside potential. On October 8, Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics to $27 from $24, while maintaining a... Full story

Yahoo Finance • 6 months ago

KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on beha... Full story

Yahoo Finance • 7 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable sa... Full story

Yahoo Finance • 7 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up​ Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025 EMERYVILLE, Calif.,... Full story

Yahoo Finance • 8 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis suppo... Full story

Yahoo Finance • 8 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that... Full story

Yahoo Finance • 8 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to in... Full story

Yahoo Finance • 9 months ago

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stoc... Full story

Yahoo Finance • 10 months ago

Kyverna Therapeutics appoints Marc Grasso as CFO

* Kyverna Therapeutics (NASDAQ:KYTX [https://seekingalpha.com/symbol/KYTX]) announced on Monday the appointment of Marc Grasso as its chief financial officer (CFO), effective today. * Most recently, Grasso served as CFO of Alector, a... Full story

Yahoo Finance • 10 months ago

Kyverna therapeutics appoints Marc Grasso as new chief financial officer

EMERYVILLE, Calif. - Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, announced today the appointment of Marc Grasso, M.D., as its new Chief Financial O... Full story

Yahoo Finance • 12 months ago

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf

PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ: KYTX): Grabar Law Office is investigating claims on behalf of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shareholders. The investigation concerns wheth... Full story